Drug Combination Details
| General Information of the Combination (ID: C74864) | |||||
|---|---|---|---|---|---|
| Name | Piperine NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | RELA | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MDA-MB-468 | CVCL_0419 | Breast adenocarcinoma | Homo sapiens | ||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| 4T1 | CVCL_0125 | Malignant neoplasms | Mus musculus | |||
| In-vivo Model | 1*105 4T1-luc murine cells were inoculated directly into the mouse mammary fat pad. | |||||
| Experimental
Result(s) |
Piperine enhances TRAIL-based therapeutics for TNBC. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Piperine enhances the efficacy of TRAIL-based therapy for triple-negative breast cancer cells. Anticancer Res. 2014 Apr;34(4):1893-9. | |||